United States research-based biopharmaceutical company AbbVie Inc. (NYSE: ABBV) announced on Friday its quarterly cash dividend.
The company has declared a quarterly cash dividend of USD1.55 per share. The dividend will be paid to shareholders of record as at 15 October 2024, on 15 November 2024.
AbbVie focuses on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and women's health, as well as through our Allergan Aesthetics portfolio.
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
Labcorp announces cash dividend
Gilead expands global access to lenacapavir for HIV prevention